Epigenetics in Cancer and Drug Therapeutics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 10 May 2026 | Viewed by 3040
Special Issue Editors
Interests: cancer; pancreatic cancer; cancer epigenetics; molecular target; cancer therapeutics
Interests: appendiceal cancer; epigenetics; translational research; cancer biomarkers; gastrointestinal cancer; precision oncology; epigenetic-specific biomarker
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epigenetics is pivotal in cancer biology, shaping the chromatin landscape and regulating gene expression dynamically and reversibly. Alterations in chromatin regulators and spatial genome organization are increasingly recognized as central drivers of cancer aggressiveness, metastasis, and therapeutic resistance. Techniques like Hi-C have illuminated how genome architecture contributes to these phenotypes, uncovering actionable vulnerabilities. Meanwhile, epigenetic therapies targeting DNMTs, HDACs, and chromatin-binding proteins have shown promise in reprogramming tumor epigenomes and enhancing immune modulation. This call for papers invites researchers to contribute innovative studies that dissect these mechanisms and explore their therapeutic implications. Together, let us advance our understanding of epigenetic plasticity in cancer and translate these findings into impactful interventions. Submit your work to help shape the future of epigenetic cancer research and therapy.
We invite submissions for a Special Issue exploring the intricate relationship between epigenetics and cancer, emphasizing translating epigenetic findings into innovative therapeutic strategies. This issue seeks to present cutting-edge research on the molecular underpinnings of cancer, focusing on chromatin regulation, spatial genome organization, and their impact on disease progression and therapeutic resistance.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- The role of chromatin remodeling complexes and histone modifiers in tumorigenesis and therapy resistance.
- Spatial genome architecture: insights from Hi-C and other 3D genome mapping techniques in understanding cancer aggressiveness and progression.
- The development and validation of DNA methylation, histone modification, or chromatin accessibility markers for diagnosis and treatment response.
- The development of small-molecule inhibitors or biologics targeting epigenetic regulators (e.g., DNMT, HDAC, proteins).
- Insights from single-cell and spatial epigenomics in dissecting intra-tumoral diversity and microenvironmental influences.
- Uncovering epigenetic mechanisms that drive metastasis, recurrence, and poor prognosis and associated therapeutic drug-based approaches.
- The synergistic use of epigenetic drugs with immune checkpoint inhibitors or other immunotherapeutics.
We look forward to receiving your contributions.
Dr. Bethsebie Sailo
Dr. Anup R. Sharma
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer epigenetics
- chromatin remodeling complexes
- histone modifiers
- DNA methylation
- molecular target
- cancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
